Table 5. Pair-wise comparisons of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma in the previous and current meta-analyses.
| Overall survival | Progression-free survival | Localregional failure-free survival | Distant failure-free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meta-analysis | Trials(N; size) | HR(95%CI) | Heterogeneity(I2, %) | Trials(N, size) | HR(95%CI) | Heterogeneity(I2, %) | Trials(N, size) | HR(95%CI) | Heterogeneity(I2, %) | Trials(N, size) | HR(95%CI) | Heterogeneity(I2, %) |
| Yan et al, 2015,[8]a | 3; 378 | 0.88(0.57–1.36) | NI | NI | NI | NI | NI | NI | NI | NI | NI | NI |
| Song et al, 2015, [6] | 3; 318 | 0.52(0.21–1.29) | 61.9 | 4; 798 | 0.66(0.49–0.90) | 0.0 | NI | NI | NI | 2; 592 | 0.60(0.39–0.98) | 0.0 |
| Liang et al, 2013, [5]b | 3; 371 | 0.99(0.72-1.36) | 0.0 | 2; 95 | 0.37(0.20-0.69) | 0.0 | 3; 347 | 1.08(0.84-1.38) | 34.0 | 2; 287 | 0.98(0.75-1.27) | 23.0 |
| Chen et al, 2015,[7]a | 2; 206 | 0.70(0.39-1.26) | 79.0 | NI | NI | NI | 2; 206 | 1.65(0.95-2.86) | 0.0 | 2; 206 | 0.51(0.28-0.95) | 0.0 |
| The present studyc | 7; 1705 | 0.64(0.49 – 0.84) | 0.0 | 9; 2215 | 0.68(0.56 – 0.81) | 0.0 | 4; 591 | 1.31(0.83 – 2.07) | 0.0 | 5; 1177 | 0.72(0.53 – 0.97) | 0.0 |
a
Shown was the pair-wise comparison included in the network meta-analysis.
b
The selected effect size for overall survival, progression-free survival, locoregional failure-free survival, and distant failure-free survival was relative risk with 95% CIs.
c
The selected effect size for locoregional failure-free survival was odds ratio with 95% CIs.
CI, confidence interval; HR, hazard ratio; NI, not investigated.